Apellis Pharmaceuticals Inc (APLS NASDAQ) stock market data APIs
$23.0772
0.64(2.8%)
as of September 17, 2025
Try our APIs with
free plan!
Apellis Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, hematopoietic stem cell transplantation-associated thrombotic microangiopathy, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
Prev. Close
23.0772
Open
23.7169
High
24.1118
Low
22.8766
52 wk Range
16.1-37.835
Market Cap
2 921 M
Shares Outstanding
126 M
Revenue
755 M
EPS
-0.33
Beta
0.723
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Apellis Pharmaceuticals Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Apellis Pharmaceuticals Inc data using free add-ons & libraries
Get Apellis Pharmaceuticals Inc Fundamental Data
Apellis Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 755 M
- EBITDA: -188 263 008
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-07-31
- EPS/Forecast: -0.48
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Apellis Pharmaceuticals Inc News
New
APLS Crosses Below Key Moving Average Level
In trading on Monday, shares of Apellis Pharmaceuticals Inc (Symbol: APLS) crossed below their 200 day moving average of $54.19, changing hands as low as $54.00 per share. Apellis Pharmaceuticals Inc...
When Can We Expect A Profit From Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)?
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Apellis Pharmaceuticals, Inc., a commercia...
Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences
WALTHAM, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that management will participate in webcast fireside chats at the following investor c...
Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences
Apellis Pharmaceuticals, Inc. WALTHAM, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that management will participate in webcast fireside chat...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
